MEDICALSYSTEM(SZ:300439)2022-04-22 16:00Profit Distribution and Financial Performance - The profit distribution plan approved by the board is to distribute a cash dividend of 0.95 yuan (including tax) for every 10 shares based on a total of 382,999,815 shares[4]. - The total cash dividend amount for the reporting period is CNY 36,384,982.43, which accounts for 100% of the distributable profit of CNY 606,124,458.57[164]. - The company’s operating revenue for 2021 was approximately ¥2.25 billion, a decrease of 2.19% compared to ¥2.30 billion in 2020[20]. - The net profit attributable to shareholders for 2021 was approximately ¥179.49 million, down 40.07% from ¥299.48 million in 2020[20]. - The total revenue for the reporting period was 2,251.53 million CNY, a decrease of 2.19% compared to the previous year[48]. - The revenue from third-party medical diagnostic services increased by 29.70% to 768.09 million CNY, driven by the company's active participation in COVID-19 testing services[48]. - The net cash flow from operating activities decreased by 43.48% to approximately ¥515.48 million in 2021 from ¥912.07 million in 2020[20]. - The company reported no significant discrepancies between quarterly and annual financial reports[23]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements and potential operational risks outlined in the report[4]. - The report includes a section on future development prospects, highlighting potential risks the company may face[4]. - The company is committed to enhancing its R&D capabilities to mitigate risks associated with new product development and technological obsolescence[127]. - The company faces risks from policy changes and industry regulations, which could adversely affect operations if not adapted to new market rules[126]. - The company has established dedicated departments to ensure timely registration of new products, which is crucial for future growth[129]. Corporate Governance and Management - All board members attended the meeting to review the annual report, ensuring comprehensive oversight[3]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, including the chairman and accounting heads[3]. - The company has improved its governance structure by enhancing internal management and control systems[134]. - The board of directors is responsible for major operational decisions and is supported by specialized committees[134]. - The company has not experienced any significant discrepancies in governance compared to regulatory requirements[135]. - The company has a performance assessment scheme for senior management approved by the board of directors[148]. - The company has a structured decision-making process for determining the remuneration of directors and supervisors, requiring approval from the board and shareholders[148]. Research and Development - The company’s R&D investment reached 150.68 million CNY, an increase of 11.22% year-on-year, enhancing its product innovation capabilities[49]. - The company has several ongoing R&D projects, including the MS-Ci4500 and MS-P1000, aimed at expanding the biochemical and immunological markets[82]. - The company achieved a research and development investment of approximately ¥150.68 million in 2021, representing 6.69% of its operating revenue, an increase from 5.89% in 2020[84]. - The number of R&D personnel increased by 22.73% from 308 in 2020 to 378 in 2021, with R&D personnel now accounting for 15.71% of the total workforce[84]. - The company is actively pursuing new product development in the field of immunoassays and biochemical analysis[90]. Market Position and Strategy - The company aims to enhance its competitiveness by developing innovative products with independent intellectual property rights, particularly in high-end diagnostic equipment and reagents[35]. - The company is positioned to benefit from the increasing demand for IVD services driven by the rise in chronic diseases and the growing health service needs of the population[33]. - The company has established a comprehensive product platform with 54 registered instruments and 377 registered reagents, making it one of the most complete suppliers in the domestic in vitro diagnostic market[38]. - The company aims to strengthen its core business and optimize its product structure to enhance its position in the IVD industry[39]. - The company is targeting the Asia-Pacific region for international market expansion, with a focus on the Philippines and Indonesia, while also promoting its main products in South Asia, the Middle East, Africa, Europe, and the Americas[124]. Social Responsibility and Environmental Initiatives - The company donated a total of RMB 1.4223 million for social responsibility initiatives, including RMB 0.2823 million in scholarships and RMB 0.5 million to the education fund in Yinzhou District[178]. - The company implemented ISO 14001 certification for environmental management, focusing on wastewater and medical waste treatment[177]. - The company has established agreements for the safe disposal of medical waste with collection centers[177]. - The company actively participated in the national poverty alleviation strategy, collaborating with medical colleges to support education[178]. Financial Management and Investments - The company raised CNY 1 billion through financing activities, with a net cash flow from financing activities of CNY 24.20 million, a significant improvement from a net outflow of CNY 774.26 million in 2020[96]. - The total assets at the end of 2021 amounted to CNY 3.59 billion, with cash and cash equivalents increasing to CNY 666.31 million, representing 18.54% of total assets[98]. - The company’s total investment for the reporting period was CNY 129.48 million, a decrease of 22.57% from CNY 167.24 million in the previous year[102]. - The company has committed RMB 170 million to the in vitro diagnostic product and industrialization project, with RMB 1.99819 million (11.75%) utilized so far[108]. Legal and Regulatory Matters - The company is involved in a lawsuit concerning a shareholder dispute, with a claimed amount of 53.63 million RMB, and the case is currently pending in court[199]. - The company has not faced any bankruptcy reorganization issues during the reporting period[198]. - The company has not reported any significant changes in its internal control audit or financial advisory arrangements[198]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[191].